Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
All participants provided written informed consent?a In EXPLORER-HCM. patients received mavacamten or placebo for 30 weeks. After trial completion and a variable washout period, patients could enroll in MAVA- LTE. with initiation of mavacamten 5 mg/day and echocardiography-guided titration. CMR assessments were conducted as previously detailed? with analyses at baseline and week 30 of EXPLORER-HCM and weeks |24 and 96 of MAVA-LTE (data extraction on March 9, (2023). Exploratory end points included left ventricular (LV) mass index, LV maximum wall thickness, volumes land function (left atrial volume maximum index, LV end- diastolic volume index, LV end-sys tolic volume index, and myocardial contractile fraction), focal and diffuse mocar- dial fibrosis (6-SD late gadolinium enhancement [LGE] and average extracellular volume fraction), and LV ejec- tion fraction (LVEF).
Authors
- Theodore P. Abraham (ORCID: https://orcid.org/0000-0001-8966-6906)
- Roberto Barriales‐Villa (ORCID: https://orcid.org/0000-0002-6721-3487)
- Artur Oręziak (ORCID: https://orcid.org/0000-0003-3318-3643)
- John C. Stendahl (ORCID: https://orcid.org/0000-0002-1568-9280)
- Ganesh Balaratnam
- Ofer Havakuk (ORCID: https://orcid.org/0000-0002-5097-2698)
- Sara Saberi (ORCID: https://orcid.org/0000-0003-4473-6725)
- Iacopo Olivotto (ORCID: https://orcid.org/0000-0003-1751-9266)
- Shawna Fox
- Nuno Cardim (ORCID: https://orcid.org/0000-0002-3812-4872)
- Christopher M. Kramer (ORCID: https://orcid.org/0000-0003-2057-7731)
- ANJALI TIKU OWENS (ORCID: https://orcid.org/0000-0002-9669-8495)
- Tim Seidler (ORCID: https://orcid.org/0000-0002-6158-5087)
- Mark V. Sherrid (ORCID: https://orcid.org/0000-0003-4972-7780)
- Neal K. Lakdawala (ORCID: https://orcid.org/0000-0001-6458-5421)
- Michael Jerosch‐Herold (ORCID: https://orcid.org/0000-0001-9018-6731)
- Ahmad Masri (ORCID: https://orcid.org/0000-0002-6390-6526)
- Florian Rader (ORCID: https://orcid.org/0000-0003-1637-5096)
- Sheila M. Hegde (ORCID: https://orcid.org/0000-0001-8157-8899)
- Raymond Y. Kwong (ORCID: https://orcid.org/0000-0001-8212-0759)
- Lubna Choudhury (ORCID: https://orcid.org/0000-0003-4039-8490)
- Andrew Wang (ORCID: https://orcid.org/0000-0001-8729-0933)
- Gregory Kurio
Institutions
- Northwestern University (US)
- Cedars-Sinai Medical Center (US)
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Duke University (US)
- University of California, San Francisco (US)
- Owens-Illinois (United States) (US)
- University of Michigan (US)
- University of Virginia Health System (US)
- Tel Aviv Sourasky Medical Center (IL)
- Yale University (US)
- NYU Langone Health (US)
- American Conservatory Theater (US)
- Meyer Children's Hospital (IT)
- Hospital da Luz (PT)
- Kerckhoff Klinik (DE)
- Bristol-Myers Squibb (Sweden) (SE)
- Institute of Cardiology (PL)
- Complexo Hospitalario Universitario A Coruña (ES)
- Instituto de Investigación Biomédica de A Coruña (ES)
- University of Virginia (US)
- University of Göttingen (DE)
Publication Details
- Journal
- Circulation
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1161/circulationaha.124.071188
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39